Methoxyamine: Phase II started

Tracon said the NCI began an open-label, U.S. Phase II trial to evaluate once-daily oral methoxyamine plus oral Temodar temozolomide on days 1-5 of a 28-day cycle in 66 patients with glioblastoma who...